|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:CREB3L2-PPARG (FusionGDB2 ID:HG64764TG5468) |
Fusion Gene Summary for CREB3L2-PPARG |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: CREB3L2-PPARG | Fusion gene ID: hg64764tg5468 | Hgene | Tgene | Gene symbol | CREB3L2 | PPARG | Gene ID | 64764 | 5468 |
| Gene name | cAMP responsive element binding protein 3 like 2 | peroxisome proliferator activated receptor gamma | |
| Synonyms | BBF2H7 | CIMT1|GLM1|NR1C3|PPARG1|PPARG2|PPARgamma | |
| Cytomap | ('CREB3L2')('PPARG') 7q33 | 3p25.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | cyclic AMP-responsive element-binding protein 3-like protein 2B-ZIB transcription factorBBF2 human homolog on chromosome 7FUS/BBF2H7 proteinTCAG_1951439basic transcription factor 2cAMP-responsive element-binding protein 3-like protein 2 | peroxisome proliferator-activated receptor gammaPPAR-gammanuclear receptor subfamily 1 group C member 3peroxisome proliferator-activated nuclear receptor gamma variant 1 | |
| Modification date | 20200313 | 20200329 | |
| UniProtAcc | Q70SY1 | P37231 | |
| Ensembl transtripts involved in fusion gene | ENST00000330387, ENST00000452463, ENST00000456390, ENST00000458726, ENST00000468127, | ||
| Fusion gene scores | * DoF score | 15 X 16 X 7=1680 | 11 X 14 X 10=1540 |
| # samples | 18 | 23 | |
| ** MAII score | log2(18/1680*10)=-3.22239242133645 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(23/1540*10)=-2.74322458463789 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: CREB3L2 [Title/Abstract] AND PPARG [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | CREB3L2(137686451)-PPARG(12421202), # samples:1 CREB3L2(137612896)-PPARG(12421202), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | CREB3L2 | GO:0045893 | positive regulation of transcription, DNA-templated | 17178827 |
| Tgene | PPARG | GO:0000122 | negative regulation of transcription by RNA polymerase II | 12700342 |
| Tgene | PPARG | GO:0006919 | activation of cysteine-type endopeptidase activity involved in apoptotic process | 18293083 |
| Tgene | PPARG | GO:0007165 | signal transduction | 9568716 |
| Tgene | PPARG | GO:0010742 | macrophage derived foam cell differentiation | 26504087 |
| Tgene | PPARG | GO:0010745 | negative regulation of macrophage derived foam cell differentiation | 19114110 |
| Tgene | PPARG | GO:0010871 | negative regulation of receptor biosynthetic process | 12700342 |
| Tgene | PPARG | GO:0010887 | negative regulation of cholesterol storage | 19114110 |
| Tgene | PPARG | GO:0010891 | negative regulation of sequestering of triglyceride | 12700342 |
| Tgene | PPARG | GO:0016525 | negative regulation of angiogenesis | 28566713 |
| Tgene | PPARG | GO:0030224 | monocyte differentiation | 9568716 |
| Tgene | PPARG | GO:0032526 | response to retinoic acid | 16239304 |
| Tgene | PPARG | GO:0042953 | lipoprotein transport | 9568716 |
| Tgene | PPARG | GO:0043537 | negative regulation of blood vessel endothelial cell migration | 28566713 |
| Tgene | PPARG | GO:0045713 | low-density lipoprotein particle receptor biosynthetic process | 9568716 |
| Tgene | PPARG | GO:0045944 | positive regulation of transcription by RNA polymerase II | 9568715|12700342|16239304|17611579 |
| Tgene | PPARG | GO:0048469 | cell maturation | 9568716 |
| Tgene | PPARG | GO:0048662 | negative regulation of smooth muscle cell proliferation | 20622039 |
| Tgene | PPARG | GO:0051091 | positive regulation of DNA-binding transcription factor activity | 18293083 |
| Tgene | PPARG | GO:0061614 | pri-miRNA transcription by RNA polymerase II | 28566713 |
| Tgene | PPARG | GO:0071404 | cellular response to low-density lipoprotein particle stimulus | 9568716 |
| Tgene | PPARG | GO:1904706 | negative regulation of vascular smooth muscle cell proliferation | 28522568 |
| Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | papilary thyroid carcinoma | AY222643 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| ChimerKB4 | . | . | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
Top |
Fusion Gene ORF analysis for CREB3L2-PPARG |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-5UTR | ENST00000330387 | ENST00000287820 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000330387 | ENST00000309576 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000330387 | ENST00000397000 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000330387 | ENST00000397010 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000330387 | ENST00000397012 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000330387 | ENST00000397015 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000330387 | ENST00000397026 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000330387 | ENST00000539812 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000452463 | ENST00000287820 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000452463 | ENST00000309576 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000452463 | ENST00000397000 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000452463 | ENST00000397010 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000452463 | ENST00000397012 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000452463 | ENST00000397015 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000452463 | ENST00000397026 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000452463 | ENST00000539812 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000456390 | ENST00000287820 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000456390 | ENST00000309576 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000456390 | ENST00000397000 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000456390 | ENST00000397010 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000456390 | ENST00000397012 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000456390 | ENST00000397015 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000456390 | ENST00000397026 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000456390 | ENST00000539812 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000458726 | ENST00000287820 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000458726 | ENST00000309576 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000458726 | ENST00000397000 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000458726 | ENST00000397010 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000458726 | ENST00000397012 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000458726 | ENST00000397015 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000458726 | ENST00000397026 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000458726 | ENST00000539812 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000468127 | ENST00000287820 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000468127 | ENST00000309576 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000468127 | ENST00000397000 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000468127 | ENST00000397010 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000468127 | ENST00000397012 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000468127 | ENST00000397015 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000468127 | ENST00000397026 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-5UTR | ENST00000468127 | ENST00000539812 | CREB3L2 | chr7 | 137686451 | PPARG | chr3 | 12421202 | ||
| intron-intron | ENST00000330387 | ENST00000287820 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000330387 | ENST00000309576 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000330387 | ENST00000397000 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000330387 | ENST00000397010 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000330387 | ENST00000397012 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000330387 | ENST00000397015 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000330387 | ENST00000397026 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000330387 | ENST00000539812 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000452463 | ENST00000287820 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000452463 | ENST00000309576 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000452463 | ENST00000397000 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000452463 | ENST00000397010 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000452463 | ENST00000397012 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000452463 | ENST00000397015 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000452463 | ENST00000397026 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000452463 | ENST00000539812 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000456390 | ENST00000287820 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000456390 | ENST00000309576 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000456390 | ENST00000397000 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000456390 | ENST00000397010 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000456390 | ENST00000397012 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000456390 | ENST00000397015 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000456390 | ENST00000397026 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000456390 | ENST00000539812 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000458726 | ENST00000287820 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000458726 | ENST00000309576 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000458726 | ENST00000397000 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000458726 | ENST00000397010 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000458726 | ENST00000397012 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000458726 | ENST00000397015 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000458726 | ENST00000397026 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000458726 | ENST00000539812 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000468127 | ENST00000287820 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000468127 | ENST00000309576 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000468127 | ENST00000397000 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000468127 | ENST00000397010 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000468127 | ENST00000397012 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000468127 | ENST00000397015 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000468127 | ENST00000397026 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| intron-intron | ENST00000468127 | ENST00000539812 | CREB3L2 | chr7 | 137613112 | - | PPARG | chr3 | 137613112 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for CREB3L2-PPARG |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| CREB3L2 | chr7 | 137612895 | - | PPARG | chr3 | 12421202 | + | 2.90E-10 | 1 |
| CREB3L2 | chr7 | 137612895 | - | PPARG | chr3 | 12421202 | + | 2.90E-10 | 1 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
 |
Top |
Fusion Protein Features for CREB3L2-PPARG |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:137686451/:12421202) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CREB3L2 | PPARG |
| FUNCTION: Transcription factor involved in unfolded protein response (UPR). In the absence of endoplasmic reticulum (ER) stress, inserted into ER membranes, with N-terminal DNA-binding and transcription activation domains oriented toward the cytosolic face of the membrane. In response to ER stress, transported to the Golgi, where it is cleaved in a site-specific manner by resident proteases S1P/MBTPS1 and S2P/MBTPS2. The released N-terminal cytosolic domain is translocated to the nucleus to effect transcription of specific target genes. Plays a critical role in chondrogenesis by activating the transcription of SEC23A, which promotes the transport and secretion of cartilage matrix proteins, and possibly that of ER biogenesis-related genes (By similarity). In a neuroblastoma cell line, protects cells from ER stress-induced death (PubMed:17178827). In vitro activates transcription of target genes via direct binding to the CRE site (PubMed:17178827). {ECO:0000250|UniProtKB:Q8BH52, ECO:0000269|PubMed:17178827}. | FUNCTION: Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity). {ECO:0000250|UniProtKB:P37238, ECO:0000269|PubMed:16150867, ECO:0000269|PubMed:20829347, ECO:0000269|PubMed:23525231, ECO:0000269|PubMed:9065481}.; FUNCTION: (Microbial infection) Upon treatment with M.tuberculosis or its lipoprotein LpqH, phosphorylation of MAPK p38 and IL-6 production are modulated, probably via this protein. {ECO:0000269|PubMed:25504154}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for CREB3L2-PPARG |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for CREB3L2-PPARG |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for CREB3L2-PPARG |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | PPARG | P37231 | DB00244 | Mesalazine | Agonist | Small molecule | Approved |
| Tgene | PPARG | P37231 | DB00244 | Mesalazine | Agonist | Small molecule | Approved |
| Tgene | PPARG | P37231 | DB00573 | Fenoprofen | Small molecule | Approved | |
| Tgene | PPARG | P37231 | DB00573 | Fenoprofen | Small molecule | Approved | |
| Tgene | PPARG | P37231 | DB00795 | Sulfasalazine | Agonist | Small molecule | Approved |
| Tgene | PPARG | P37231 | DB00795 | Sulfasalazine | Agonist | Small molecule | Approved |
| Tgene | PPARG | P37231 | DB01050 | Ibuprofen | Activator | Small molecule | Approved |
| Tgene | PPARG | P37231 | DB01050 | Ibuprofen | Activator | Small molecule | Approved |
| Tgene | PPARG | P37231 | DB02266 | Flufenamic acid | Agonist | Small molecule | Approved |
| Tgene | PPARG | P37231 | DB02266 | Flufenamic acid | Agonist | Small molecule | Approved |
| Tgene | PPARG | P37231 | DB13873 | Fenofibric acid | Small molecule | Approved | |
| Tgene | PPARG | P37231 | DB13873 | Fenofibric acid | Small molecule | Approved | |
| Tgene | PPARG | P37231 | DB11672 | Curcumin | Small molecule | Approved|Experimental|Investigational | |
| Tgene | PPARG | P37231 | DB11672 | Curcumin | Small molecule | Approved|Experimental|Investigational | |
| Tgene | PPARG | P37231 | DB00313 | Valproic acid | Small molecule | Approved|Investigational | |
| Tgene | PPARG | P37231 | DB00313 | Valproic acid | Small molecule | Approved|Investigational | |
| Tgene | PPARG | P37231 | DB00328 | Indomethacin | Activator | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB00328 | Indomethacin | Activator | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB00412 | Rosiglitazone | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB00412 | Rosiglitazone | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB00731 | Nateglinide | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB00731 | Nateglinide | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB00845 | Clofazimine | Modulator | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB00845 | Clofazimine | Modulator | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB00912 | Repaglinide | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB00912 | Repaglinide | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB00966 | Telmisartan | Partial agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB00966 | Telmisartan | Partial agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB01014 | Balsalazide | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB01014 | Balsalazide | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB01067 | Glipizide | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB01067 | Glipizide | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB01118 | Amiodarone | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB01118 | Amiodarone | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB01132 | Pioglitazone | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB01132 | Pioglitazone | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB01393 | Bezafibrate | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB01393 | Bezafibrate | Agonist | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB03756 | Doconexent | Ligand | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB03756 | Doconexent | Ligand | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB08604 | Triclosan | Small molecule | Approved|Investigational | |
| Tgene | PPARG | P37231 | DB08604 | Triclosan | Small molecule | Approved|Investigational | |
| Tgene | PPARG | P37231 | DB09061 | Cannabidiol | Activator | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB09061 | Cannabidiol | Activator | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB09213 | Dexibuprofen | Activator | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB09213 | Dexibuprofen | Activator | Small molecule | Approved|Investigational |
| Tgene | PPARG | P37231 | DB00132 | alpha-Linolenic acid | Small molecule | Approved|Investigational|Nutraceutical | |
| Tgene | PPARG | P37231 | DB00132 | alpha-Linolenic acid | Small molecule | Approved|Investigational|Nutraceutical | |
| Tgene | PPARG | P37231 | DB04224 | Oleic Acid | Ligand | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | PPARG | P37231 | DB04224 | Oleic Acid | Ligand | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | PPARG | P37231 | DB00197 | Troglitazone | Agonist | Small molecule | Approved|Investigational|Withdrawn |
| Tgene | PPARG | P37231 | DB00197 | Troglitazone | Agonist | Small molecule | Approved|Investigational|Withdrawn |
| Tgene | PPARG | P37231 | DB00159 | Icosapent | Agonist | Small molecule | Approved|Nutraceutical |
| Tgene | PPARG | P37231 | DB00159 | Icosapent | Agonist | Small molecule | Approved|Nutraceutical |
| Tgene | PPARG | P37231 | DB11133 | Omega-3 fatty acids | Ligand | Small molecule | Approved|Nutraceutical |
| Tgene | PPARG | P37231 | DB11133 | Omega-3 fatty acids | Ligand | Small molecule | Approved|Nutraceutical |
| Tgene | PPARG | P37231 | DB13961 | Fish oil | Biotech | Approved|Nutraceutical | |
| Tgene | PPARG | P37231 | DB13961 | Fish oil | Biotech | Approved|Nutraceutical |
Top |
Related Diseases for CREB3L2-PPARG |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 6 | CTD_human;GENOMICS_ENGLAND | |
| Tgene | C0238463 | Papillary thyroid carcinoma | 4 | ORPHANET | |
| Tgene | C0002152 | Alloxan Diabetes | 3 | CTD_human | |
| Tgene | C0002395 | Alzheimer's Disease | 3 | CTD_human | |
| Tgene | C0011265 | Presenile dementia | 3 | CTD_human | |
| Tgene | C0011853 | Diabetes Mellitus, Experimental | 3 | CTD_human | |
| Tgene | C0020538 | Hypertensive disease | 3 | CTD_human | |
| Tgene | C0021655 | Insulin Resistance | 3 | CTD_human | |
| Tgene | C0022660 | Kidney Failure, Acute | 3 | CTD_human | |
| Tgene | C0028754 | Obesity | 3 | CTD_human;GENOMICS_ENGLAND;UNIPROT | |
| Tgene | C0035126 | Reperfusion Injury | 3 | CTD_human | |
| Tgene | C0038433 | Streptozotocin Diabetes | 3 | CTD_human | |
| Tgene | C0276496 | Familial Alzheimer Disease (FAD) | 3 | CTD_human | |
| Tgene | C0494463 | Alzheimer Disease, Late Onset | 3 | CTD_human | |
| Tgene | C0546126 | Acute Confusional Senile Dementia | 3 | CTD_human | |
| Tgene | C0750900 | Alzheimer's Disease, Focal Onset | 3 | CTD_human | |
| Tgene | C0750901 | Alzheimer Disease, Early Onset | 3 | CTD_human | |
| Tgene | C0920563 | Insulin Sensitivity | 3 | CTD_human | |
| Tgene | C1565662 | Acute Kidney Insufficiency | 3 | CTD_human | |
| Tgene | C1720861 | Familial Partial Lipodystrophy, Type 3 | 3 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
| Tgene | C2609414 | Acute kidney injury | 3 | CTD_human | |
| Tgene | C0021368 | Inflammation | 2 | CTD_human | |
| Tgene | C0022116 | Ischemia | 2 | CTD_human | |
| Tgene | C0024623 | Malignant neoplasm of stomach | 2 | CTD_human | |
| Tgene | C0025202 | melanoma | 2 | CTD_human | |
| Tgene | C0030297 | Pancreatic Neoplasm | 2 | CTD_human | |
| Tgene | C0038356 | Stomach Neoplasms | 2 | CTD_human | |
| Tgene | C0346647 | Malignant neoplasm of pancreas | 2 | CTD_human | |
| Tgene | C1708349 | Hereditary Diffuse Gastric Cancer | 2 | CTD_human | |
| Tgene | C0001418 | Adenocarcinoma | 1 | CTD_human | |
| Tgene | C0004153 | Atherosclerosis | 1 | CTD_human | |
| Tgene | C0004763 | Barrett Esophagus | 1 | CTD_human | |
| Tgene | C0007102 | Malignant tumor of colon | 1 | CTD_human;UNIPROT | |
| Tgene | C0009375 | Colonic Neoplasms | 1 | CTD_human | |
| Tgene | C0009402 | Colorectal Carcinoma | 1 | CTD_human | |
| Tgene | C0009404 | Colorectal Neoplasms | 1 | CTD_human | |
| Tgene | C0010346 | Crohn Disease | 1 | CTD_human | |
| Tgene | C0011849 | Diabetes Mellitus | 1 | CTD_human | |
| Tgene | C0011859 | Lipoatrophic Diabetes Mellitus | 1 | ORPHANET | |
| Tgene | C0011881 | Diabetic Nephropathy | 1 | CTD_human | |
| Tgene | C0017658 | Glomerulonephritis | 1 | CTD_human | |
| Tgene | C0017667 | Nodular glomerulosclerosis | 1 | CTD_human | |
| Tgene | C0018801 | Heart failure | 1 | CTD_human | |
| Tgene | C0018802 | Congestive heart failure | 1 | CTD_human | |
| Tgene | C0023212 | Left-Sided Heart Failure | 1 | CTD_human | |
| Tgene | C0023645 | Lichen planus follicularis | 1 | GENOMICS_ENGLAND | |
| Tgene | C0023794 | Lipoidosis | 1 | CTD_human | |
| Tgene | C0023903 | Liver neoplasms | 1 | CTD_human | |
| Tgene | C0025517 | Metabolic Diseases | 1 | CTD_human | |
| Tgene | C0027746 | Nerve Degeneration | 1 | CTD_human | |
| Tgene | C0029408 | Degenerative polyarthritis | 1 | CTD_human | |
| Tgene | C0030246 | Pustulosis of Palms and Soles | 1 | CTD_human | |
| Tgene | C0030625 | Passive Cutaneous Anaphylaxis | 1 | GENOMICS_ENGLAND | |
| Tgene | C0033860 | Psoriasis | 1 | CTD_human | |
| Tgene | C0035078 | Kidney Failure | 1 | CTD_human | |
| Tgene | C0038525 | Subarachnoid Hemorrhage | 1 | CTD_human | |
| Tgene | C0040136 | Thyroid Neoplasm | 1 | CTD_human | |
| Tgene | C0079772 | T-Cell Lymphoma | 1 | CTD_human | |
| Tgene | C0085278 | Antiphospholipid Syndrome | 1 | CTD_human | |
| Tgene | C0085413 | Polycystic Kidney, Autosomal Dominant | 1 | CTD_human | |
| Tgene | C0086743 | Osteoarthrosis Deformans | 1 | CTD_human | |
| Tgene | C0086873 | Pseudopelade | 1 | GENOMICS_ENGLAND | |
| Tgene | C0151468 | Thyroid Gland Follicular Adenoma | 1 | CTD_human | |
| Tgene | C0156147 | Crohn's disease of large bowel | 1 | CTD_human | |
| Tgene | C0205641 | Adenocarcinoma, Basal Cell | 1 | CTD_human | |
| Tgene | C0205642 | Adenocarcinoma, Oxyphilic | 1 | CTD_human | |
| Tgene | C0205643 | Carcinoma, Cribriform | 1 | CTD_human | |
| Tgene | C0205644 | Carcinoma, Granular Cell | 1 | CTD_human | |
| Tgene | C0205645 | Adenocarcinoma, Tubular | 1 | CTD_human | |
| Tgene | C0206726 | gliosarcoma | 1 | ORPHANET | |
| Tgene | C0221032 | Familial generalized lipodystrophy | 1 | ORPHANET | |
| Tgene | C0221406 | Pituitary-dependent Cushing's disease | 1 | CTD_human | |
| Tgene | C0235527 | Heart Failure, Right-Sided | 1 | CTD_human | |
| Tgene | C0236811 | Chronobiology Disorders | 1 | CTD_human | |
| Tgene | C0242339 | Dyslipidemias | 1 | CTD_human | |
| Tgene | C0242488 | Acute Lung Injury | 1 | CTD_human | |
| Tgene | C0267380 | Crohn's disease of the ileum | 1 | CTD_human | |
| Tgene | C0270192 | Perinatal Subarachnoid Hemorrhage | 1 | CTD_human | |
| Tgene | C0271694 | Familial partial lipodystrophy | 1 | CTD_human | |
| Tgene | C0282548 | Leukostasis | 1 | CTD_human | |
| Tgene | C0334588 | Giant Cell Glioblastoma | 1 | ORPHANET | |
| Tgene | C0345904 | Malignant neoplasm of liver | 1 | CTD_human | |
| Tgene | C0472383 | Subarachnoid Hemorrhage, Spontaneous | 1 | CTD_human | |
| Tgene | C0525045 | Mood Disorders | 1 | PSYGENET | |
| Tgene | C0549473 | Thyroid carcinoma | 1 | CTD_human | |
| Tgene | C0598784 | Dyslipoproteinemias | 1 | CTD_human | |
| Tgene | C0678202 | Regional enteritis | 1 | CTD_human | |
| Tgene | C0751220 | Inappropriate ACTH Secretion Syndrome | 1 | CTD_human | |
| Tgene | C0751530 | Subarachnoid Hemorrhage, Aneurysmal | 1 | CTD_human | |
| Tgene | C0795688 | Subarachnoid Hemorrhage, Intracranial | 1 | CTD_human | |
| Tgene | C0813142 | Circadian Rhythm Disorders | 1 | CTD_human | |
| Tgene | C0887800 | Psychogenic Inversion of Circadian Rhythm | 1 | CTD_human | |
| Tgene | C0887850 | Polycystic Kidney, Type 1 Autosomal Dominant Disease | 1 | CTD_human | |
| Tgene | C0949272 | IIeocolitis | 1 | CTD_human | |
| Tgene | C1258085 | Barrett Epithelium | 1 | CTD_human | |
| Tgene | C1563937 | Atherogenesis | 1 | CTD_human | |
| Tgene | C1565489 | Renal Insufficiency | 1 | CTD_human | |
| Tgene | C1704377 | Bright Disease | 1 | CTD_human | |
| Tgene | C1720859 | Familial Partial Lipodystrophy, Type 1 | 1 | CTD_human | |
| Tgene | C1720860 | Familial Partial Lipodystrophy, Type 2 | 1 | CTD_human | |
| Tgene | C1959583 | Myocardial Failure | 1 | CTD_human | |
| Tgene | C1961112 | Heart Decompensation | 1 | CTD_human | |
| Tgene | C2239176 | Liver carcinoma | 1 | CTD_human | |
| Tgene | C2751306 | Polycystic kidney disease, type 2 | 1 | CTD_human | |
| Tgene | C2931367 | Thyroid cancer, follicular | 1 | CTD_human | |
| Tgene | C2936846 | Scarring alopecia | 1 | GENOMICS_ENGLAND |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies